Ucb Pharma, S.a.

Genentech, Inc.

F. Hoffmann-la Roche Ag

Ucb Biopharma Sprl

Mizio Matteucci

Andrew Sharpe

Alan Findlay Haughan

Roland W Bürli

Gilles Raphy

Andrew Pate Owens

Xiaojing Wang

Minghua Sun

Julien Alistair Brown

Vickie H Tsui

Alastair James Hodges

Daniel Rees Allen

Elizabeth Anne Saville-Stones

Jonathan David MacDonald

David John Nash

Roland BÜRLI

Jonathan David Macdonald

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Triazine derivatives as kinase inhibitors

A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Quinoline derivatives as kinase inhibitors

A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Growing community of inventors

Saffron Walden, United Kingdom

Mizio Matteucci